Inflation type one error: FDA [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2019-11-10 11:33 (321 d 20:53 ago) – Posting: # 20780
Views: 1,510

Hi Mikalai,

» […] what regulators say on this subject? I do not remember any reflection on this matter in official documents (EMA, FDA)?

Some slides of Terry Hyslop (Director, Division of Biostatistics) of his presentation “Bioequivalence (BE) for Highly Variable Drugs” at the AAPS Workshop (New Orleans, Nov 2010) – after the progesterone guidance was published…


Aka the ‘implied limits’ (see this post and slide 23 below).


Well roared, lion! Trouble starts because we use \(s_{WR}\) instead of the unknown \(\sigma_{WR}\).
Nasty but \(s_{WR}\) is all we have.
Typo, should read
… use scaled average BE if sWR > cutoff.


Illegible text (white with grey shadowing):
  assuming no subject-by-formulation interaction, σWT = σWR,
  true GMR = max (1.25, implied scaled BE limit)




res        <- data.frame(method = c("ABE", "RSABE"), TIE = NA)
res$TIE[1] <- power.TOST(CV = 0.3, n = 36, theta0 = 1.25,
                         design ="2x3x3")
res$TIE[2] <- power.RSABE(CV = 0.3, n = 36, theta0 = 1.25,
                          design ="2x3x3", nsims = 1e6)
res$TIE    <- signif(res$TIE, 4)
print(res, row.names = FALSE)

# method    TIE
#    ABE
#  RSABE 0.1323

Hence, the FDA was well aware of the inflated type I error and decided to ignore it.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,076 posts in 4,394 threads, 1,469 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Sunday 09:26 CEST (Europe/Vienna)

Politicians use statistics like drunkards use lampposts:
not for illumination, but for support.    attributed to Hans Kuhn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz